Leslie J. De Groot
Research Subjects
Leslie J. De Groot has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
William Martin
3 shared publications- Anne Searls De Groot
EpiVax, Inc, Providence, USA
2 shared publications Deshun Pan
Department of Cellular and Molecular Biology, University of Rhode Island, Providence, Rhode Island
2 shared publicationsHidefumi Inaba
Department of Cellular and Molecular Biology, University of Rhode Island, 80 Washington Street, Providence, Rhode Island 02903, USA
2 shared publicationsMatt Ardito
University of Rhode Island, and Epivax, Inc. (W.M., M.A., S.D.G.) Providence, Rhode Island 02903
2 shared publicationsD. Pan
Brown University
1 shared publication
Latest Publications
- Open Access
- 1 June 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (6) , 2909-2916
The Role of Glutamic or Aspartic Acid in Position Four of the Epitope Binding Motif and Thyrotropin Receptor-Extracellular Domain Epitope Selection in Graves’ Disease
Context: Development of Graves’ disease (GD) is related to HLA-DRB1*0301 (DR3),and more specifically to arginine at position 74 of the DRB1 molecule. The extracellular domain (ECD) of human TSH receptor (hTSH-R) contains the target antigen. Objective and Design: We analyzed the relation between hTSH-R-ECD peptides and DR molecules to determine whether aspartic acid (D) or glutamic acid (E) at position four in the binding motif influenced selection of functional epitopes. Results: Peptide epitopes from TSH-R-ECD with D or E in position four (D/E+) had higher affinity for binding to DR3 than peptides without D/E (D/E−) (IC50 29.3 vs. 61.4, P = 0.0024). HLA-DR7, negatively correlated with GD, and DRB1*0302 (HLA-DR18), not associated with GD, had different profiles of epitope binding. Toxic GD patients who are DR3+ had higher responses to D/E+ peptides than D/E− peptides (stimulation index 1.42 vs. 1.22, P = 0.028). All DR3+ GD patients (toxic + euthyroid) had higher responses, with borderline significance (Sl; 1.32 vs. 1.18, P = 0.051). Splenocytes of DR3 transgenic mice immunized to TSH-R-ECD responded to D/E+ peptides more than D/E− peptides (stimulation index 1.95 vs. 1.69, P = 0.036). Seven of nine hTSH-R-ECD peptide epitopes reported to be reactive with GD patients’ peripheral blood mononuclear cells contain binding motifs with D/E at position four. Conclusions: TSH-R-ECD epitopes with D/E in position four of the binding motif bind more strongly to DRB1*0301 than epitopes that are D/E− and are more stimulatory to GD patients’ peripheral blood mononuclear cells and to splenocytes from mice immunized to hTSH-R. These epitopes appear important in immunogenicity to TSH-R due to their favored binding to HLA-DR3, thus increasing presentation to T cells.
- 1 June 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (6) , 2909-2916
Open AccessThe Role of Glutamic or Aspartic Acid in Position Four of the Epitope Binding Motif and Thyrotropin Receptor-Extracellular Domain Epitope Selection in Graves’ Disease
Context: Development of Graves’ disease (GD) is related to HLA-DRB1*0301 (DR3),and more specifically to arginine at position 74 of the DRB1 molecule. The extracellular domain (ECD) of human TSH receptor (hTSH-R) contains the target antigen. Objective and Design: We analyzed the relation between hTSH-R-ECD peptides and DR molecules to determine whether aspartic acid (D) or glutamic acid (E) at position four in the binding motif influenced selection of functional epitopes. Results: Peptide epitopes from TSH-R-ECD with D or E in position four (D/E+) had higher affinity for binding to DR3 than peptides without D/E (D/E−) (IC50 29.3 vs. 61.4, P = 0.0024). HLA-DR7, negatively correlated with GD, and DRB1*0302 (HLA-DR18), not associated with GD, had different profiles of epitope binding. Toxic GD patients who are DR3+ had higher responses to D/E+ peptides than D/E− peptides (stimulation index 1.42 vs. 1.22, P = 0.028). All DR3+ GD patients (toxic + euthyroid) had higher responses, with borderline significance (Sl; 1.32 vs. 1.18, P = 0.051). Splenocytes of DR3 transgenic mice immunized to TSH-R-ECD responded to D/E+ peptides more than D/E− peptides (stimulation index 1.95 vs. 1.69, P = 0.036). Seven of nine hTSH-R-ECD peptide epitopes reported to be reactive with GD patients’ peripheral blood mononuclear cells contain binding motifs with D/E at position four. Conclusions: TSH-R-ECD epitopes with D/E in position four of the binding motif bind more strongly to DRB1*0301 than epitopes that are D/E− and are more stimulatory to GD patients’ peripheral blood mononuclear cells and to splenocytes from mice immunized to hTSH-R. These epitopes appear important in immunogenicity to TSH-R due to their favored binding to HLA-DR3, thus increasing presentation to T cells.
- 1 June 2010
- Published by The Endocrine Society
- p. OR37-1
The Role of Glutamic or Aspartic Acid in Position Four of the Epitope Binding Motif and TSH-R-ECD Epitope Selection in Graves' Disease.
Development of Graves' disease (GD) is related statisticallt to inheritance of HLA-DRB1*0301 (DR3), and more specifically of arginine at position 74 of the DRB1 molecule. ARG 74 is important in the shape and charge of pocket 4 in the binding cleft of DR3 protein, and is thus important in allowing or rejecting peptide binding and thus presentation on APCs. The extracellular domain (ECD) of human TSH receptor (hTSH) contains the target antigen in GD, segments of which end up on the cell surface of APCs bound to DR protein. We analyzed the relation between hTSH-R-ECD peptides and DR molecules. We asked whether the presence of amino acids carrying a negative charge such as aspartic acid (D) or glutamic acid (E) at position four in the binding motif (cognate to pocket 4) influenced selection of functional epitopes. Peptide epitopes from TSH-R-ECD with D or E in position four (D/E+) had higher affinity for binding to DR3 than peptides without D/E (D/E-) (IC50= 29.3uM vs. 61.4uM, P=0.0024). HLA-DR7, negatively correlated with GD, and DRB1*0302 (HLA-DR18), not associated with GD, had different profiles of epitope binding. PBMC from toxic GD patients who are DR3+ had higher responses to D/E+ peptides during in vitro proliferation assays than to D/E- peptides (SI; 1.42 vs. 1.22, p=0.028). All DR3+ GD patients (toxic + euthyroid) had higher responses, with borderline significance (SI; 1.32 vs. 1.18, p=0.051). DR3- patients did not have this association. Splenocytes of DR3 transgenic mice immunized to TSH-R-ECD responded during in vitro proliferation assay to D/E+ peptides more than D/E- peptides (SI; 1.95 vs. 1.69, p=0.036). Seven of 9 hTSH-R-ECD peptide epitopes previously reported to be reactive with GD patient's PBMC contain DR3 epitope binding motifs with D/E at position four. Conclusions-TSH-R-ECD epitopes with D/E in position four of the DR3 peptide binding motif bind more strongly to DRB1*0301 than epitopes which are D/E-, are more stimulatory to GD patient's PBMC, and to splenocytes from mice immunized to hTSH-R. These epitopes appear important in immunogenicity to TSH-R, due to their favored binding to HLA-DR3, thus increasing presentation to T cells. This study presents a new paradigm in recognizing epitopes involved in autoimmune diseases, through recognition of specific interactions between aminoacids forming the disease related DR protein epitope binding cleft, and cognate aminoacids in the binding motif of the epitope. Disclosures: WM: Researcher, EPIVAX, INC. MA: Researcher, EPIVAX, INC. ASDG: Speaker, EPIVAX, INC. Nothing to Disclose: LJDG, HI
- 1 June 2010
- Published by The Endocrine Society
- p. OR37-1
The Role of Glutamic or Aspartic Acid in Position Four of the Epitope Binding Motif and TSH-R-ECD Epitope Selection in Graves' Disease.
Development of Graves' disease (GD) is related statisticallt to inheritance of HLA-DRB1*0301 (DR3), and more specifically of arginine at position 74 of the DRB1 molecule. ARG 74 is important in the shape and charge of pocket 4 in the binding cleft of DR3 protein, and is thus important in allowing or rejecting peptide binding and thus presentation on APCs. The extracellular domain (ECD) of human TSH receptor (hTSH) contains the target antigen in GD, segments of which end up on the cell surface of APCs bound to DR protein. We analyzed the relation between hTSH-R-ECD peptides and DR molecules. We asked whether the presence of amino acids carrying a negative charge such as aspartic acid (D) or glutamic acid (E) at position four in the binding motif (cognate to pocket 4) influenced selection of functional epitopes. Peptide epitopes from TSH-R-ECD with D or E in position four (D/E+) had higher affinity for binding to DR3 than peptides without D/E (D/E-) (IC50= 29.3uM vs. 61.4uM, P=0.0024). HLA-DR7, negatively correlated with GD, and DRB1*0302 (HLA-DR18), not associated with GD, had different profiles of epitope binding. PBMC from toxic GD patients who are DR3+ had higher responses to D/E+ peptides during in vitro proliferation assays than to D/E- peptides (SI; 1.42 vs. 1.22, p=0.028). All DR3+ GD patients (toxic + euthyroid) had higher responses, with borderline significance (SI; 1.32 vs. 1.18, p=0.051). DR3- patients did not have this association. Splenocytes of DR3 transgenic mice immunized to TSH-R-ECD responded during in vitro proliferation assay to D/E+ peptides more than D/E- peptides (SI; 1.95 vs. 1.69, p=0.036). Seven of 9 hTSH-R-ECD peptide epitopes previously reported to be reactive with GD patient's PBMC contain DR3 epitope binding motifs with D/E at position four. Conclusions-TSH-R-ECD epitopes with D/E in position four of the DR3 peptide binding motif bind more strongly to DRB1*0301 than epitopes which are D/E-, are more stimulatory to GD patient's PBMC, and to splenocytes from mice immunized to hTSH-R. These epitopes appear important in immunogenicity to TSH-R, due to their favored binding to HLA-DR3, thus increasing presentation to T cells. This study presents a new paradigm in recognizing epitopes involved in autoimmune diseases, through recognition of specific interactions between aminoacids forming the disease related DR protein epitope binding cleft, and cognate aminoacids in the binding motif of the epitope. Disclosures: WM: Researcher, EPIVAX, INC. MA: Researcher, EPIVAX, INC. ASDG: Speaker, EPIVAX, INC. Nothing to Disclose: LJDG, HI
- 1 November 2009
- Published by SAGE Publications in Thyroid®
- Vol. 19 (11) , 1271-1280
Immune Response of Mice Transgenic for Human Histocompatibility Leukocyte Antigen-DR to Human Thyrotropin Receptor-Extracellular Domain
Background: Hyperthyroidism of Graves' disease is caused by auto-antibodies to human thyrotropin receptor (hTSH-R). To elucidate important T-cell epitopes in TSH-R, we studied three models of immunity to TSH-R in mice. Methods: Mice transgenic for histocompatibility leukocyte antigen DR3 or DR2 were immunized with cDNA for hTSH-R-extracellular domain (hTSH-R-ECD), or hTSH-R-ECD protein, or hTSH-R peptide epitopes. Proliferative responses of immunized splenocytes to epitopes derived from the hTSH-ECD sequence, anti-TSH-R antibody responses, serum thyroxine and TSH, and thyroid histology were recorded. Results: DR3 mice responded to genomic immunization with proliferative responses to several epitopes, which increased in intensity and spread to include more epitopes, during a 6-week immunization program. DR2 transgenic mice developed weak proliferative responses. Both types of mice developed anti-TSH-R antibodies measured by enzyme-linked immunosorbent assay or TSH-binding inhibition assay in 16–60% of animals. There was evidence of weak thyroid stimulation in one group of animals. Immunization of DR3 transgenic mice to hTSH-R-ECD protein induced a striking response to an epitope with sequence ISRIYVSIDVTLQQLES (aa78–94). Immunization to peptides derived from the TSH-R-ECD sequence (including aa78–94) caused strong responses to the epitopes, and development of immune responses to several other nonoverlapping epitopes within the hTSH sequence (epitope spreading) and antibodies reacting with hTSH-R. This implies that immunization with hTSH-R epitopes produced immunity to mouse TSH-R. Conclusion: T-cell and B-cell responses to genetic immunization differ in DR3 and DR2 transgenic mice, and there is less genetic control of antibody than of T-cell responses. During both genomic and peptide epitope immunization there was evidence of epitope spreading during the immunization. Several functionally important epitopes are evident, especially aa78–94. However, if similar progressive epitope recruitment occurs in human disease, epitope-based therapy will be difficult to achieve.
- 1 November 2009
- Published by SAGE Publications in Thyroid®
- Vol. 19 (11) , 1271-1280
Immune Response of Mice Transgenic for Human Histocompatibility Leukocyte Antigen-DR to Human Thyrotropin Receptor-Extracellular Domain
Background: Hyperthyroidism of Graves' disease is caused by auto-antibodies to human thyrotropin receptor (hTSH-R). To elucidate important T-cell epitopes in TSH-R, we studied three models of immunity to TSH-R in mice. Methods: Mice transgenic for histocompatibility leukocyte antigen DR3 or DR2 were immunized with cDNA for hTSH-R-extracellular domain (hTSH-R-ECD), or hTSH-R-ECD protein, or hTSH-R peptide epitopes. Proliferative responses of immunized splenocytes to epitopes derived from the hTSH-ECD sequence, anti-TSH-R antibody responses, serum thyroxine and TSH, and thyroid histology were recorded. Results: DR3 mice responded to genomic immunization with proliferative responses to several epitopes, which increased in intensity and spread to include more epitopes, during a 6-week immunization program. DR2 transgenic mice developed weak proliferative responses. Both types of mice developed anti-TSH-R antibodies measured by enzyme-linked immunosorbent assay or TSH-binding inhibition assay in 16–60% of animals. There was evidence of weak thyroid stimulation in one group of animals. Immunization of DR3 transgenic mice to hTSH-R-ECD protein induced a striking response to an epitope with sequence ISRIYVSIDVTLQQLES (aa78–94). Immunization to peptides derived from the TSH-R-ECD sequence (including aa78–94) caused strong responses to the epitopes, and development of immune responses to several other nonoverlapping epitopes within the hTSH sequence (epitope spreading) and antibodies reacting with hTSH-R. This implies that immunization with hTSH-R epitopes produced immunity to mouse TSH-R. Conclusion: T-cell and B-cell responses to genetic immunization differ in DR3 and DR2 transgenic mice, and there is less genetic control of antibody than of T-cell responses. During both genomic and peptide epitope immunization there was evidence of epitope spreading during the immunization. Several functionally important epitopes are evident, especially aa78–94. However, if similar progressive epitope recruitment occurs in human disease, epitope-based therapy will be difficult to achieve.
- 7 September 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (4) , 587-593
Regulatory T cells in Graves’ disease
Context Graves’ disease (GD) involves auto‐immunity against thyroid cell antigens, but the reasons for induction of auto‐immunity are uncertain. We wished to determine whether there was a deficiency of regulatory T cells in patients with active GD. Design Venous blood samples were obtained from patients with GD before and after treatment, and controls, and peripheral blood mononuclear cells were prepared. Patients and measurements Regulatory T cells were enumerated by Fluorescent Activated Cell sorting (FACS) in nineteen patients with untreated GD, 9 patients 6–8 weeks post RAI therapy, and 30 control subjects. Twenty‐one patients with active GD prior to control of hyperthyroidism, 23 euthyroid controls without known autoimmune thyroid disease, and 10 patients who were euthyroid 6–12 months after RAI treatment were studied for expression of genes found in regulatory T cells by real‐time Polymerase Chain reaction (PCR). Results Percent distribution of CD4+, CD4+CD25+ and CD4+ CD25+int‐hi CD127+lo regulatory T cells was similar in active GD patients and control subjects. The number of CD25+ and CD4+ CD25+int‐hi CD127+lo cells was similar in GD patients and control subjects, but was lower in recently treated patients. Messenger RNA was prepared from PBMC, and reverse transcribed. Copy DNA abundance was evaluated by Real Time PCR using appropriate primers, for GAPDH (glyceraldehyde phosphate dehydrogenase) as a control housekeeping gene, and 5 genes related to function of regulatory T cells. Message RNA for Gadd45 alpha, Gadd45beta (growth arrest and damage inducible proteins), GITR (glucocorticoid inducible TNF receptor) and CD25 (IL‐2R subunit) was more abundant in patients with active GD than in normal controls, and FoxP3 mRNA level was equal to that in controls. Message RNA levels in patients treated and euthyroid for 6 months were also greater than or equal to values in controls. Conclusion This study provides evidence that there is no deficit in T regulatory cells during active GD, or during the months post therapy.
- 7 September 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (4) , 587-593
Regulatory T cells in Graves’ disease
Context Graves’ disease (GD) involves auto‐immunity against thyroid cell antigens, but the reasons for induction of auto‐immunity are uncertain. We wished to determine whether there was a deficiency of regulatory T cells in patients with active GD. Design Venous blood samples were obtained from patients with GD before and after treatment, and controls, and peripheral blood mononuclear cells were prepared. Patients and measurements Regulatory T cells were enumerated by Fluorescent Activated Cell sorting (FACS) in nineteen patients with untreated GD, 9 patients 6–8 weeks post RAI therapy, and 30 control subjects. Twenty‐one patients with active GD prior to control of hyperthyroidism, 23 euthyroid controls without known autoimmune thyroid disease, and 10 patients who were euthyroid 6–12 months after RAI treatment were studied for expression of genes found in regulatory T cells by real‐time Polymerase Chain reaction (PCR). Results Percent distribution of CD4+, CD4+CD25+ and CD4+ CD25+int‐hi CD127+lo regulatory T cells was similar in active GD patients and control subjects. The number of CD25+ and CD4+ CD25+int‐hi CD127+lo cells was similar in GD patients and control subjects, but was lower in recently treated patients. Messenger RNA was prepared from PBMC, and reverse transcribed. Copy DNA abundance was evaluated by Real Time PCR using appropriate primers, for GAPDH (glyceraldehyde phosphate dehydrogenase) as a control housekeeping gene, and 5 genes related to function of regulatory T cells. Message RNA for Gadd45 alpha, Gadd45beta (growth arrest and damage inducible proteins), GITR (glucocorticoid inducible TNF receptor) and CD25 (IL‐2R subunit) was more abundant in patients with active GD than in normal controls, and FoxP3 mRNA level was equal to that in controls. Message RNA levels in patients treated and euthyroid for 6 months were also greater than or equal to values in controls. Conclusion This study provides evidence that there is no deficit in T regulatory cells during active GD, or during the months post therapy.
- 1 January 2009
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 32 (1) , 52-56
Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves’ disease
In Graves' disease (GD) immunized T cells reactive to TSH-receptor epitopes contribute to pathogenesis through B cell help, and cytotoxicity. We evaluated T cell responses to synthetic TSH-receptor epitopes in hyperthyroid patients with GD prior to therapy, at 6-8 weeks after radioactive iodine (RAI) administration, or 6-8 months later when euthyroid, and in control subjects. All T cell responses were relatively low as generally found in human autoimmune diseases. Responses in hyperthyroid GD patients were significantly greater than among controls, were augmented 6-8 weeks after RAI treatment, were still present after patients became euthyroid, and did not differ between DR3+ and non-DR3+ patients. Patient's T cells reacted to multiple different epitopes, and reactivity differed depending on the course of the disease and treatment.While certain epitopes most commonly cause T cell reactivity, we did not find evidence for a single or few "dominant" epitopes.
- 1 January 2009
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 32 (1) , 52-56
Evaluation of T cell stimulation by thyrotropin-receptor epitopes in Graves’ disease
In Graves' disease (GD) immunized T cells reactive to TSH-receptor epitopes contribute to pathogenesis through B cell help, and cytotoxicity. We evaluated T cell responses to synthetic TSH-receptor epitopes in hyperthyroid patients with GD prior to therapy, at 6-8 weeks after radioactive iodine (RAI) administration, or 6-8 months later when euthyroid, and in control subjects. All T cell responses were relatively low as generally found in human autoimmune diseases. Responses in hyperthyroid GD patients were significantly greater than among controls, were augmented 6-8 weeks after RAI treatment, were still present after patients became euthyroid, and did not differ between DR3+ and non-DR3+ patients. Patient's T cells reacted to multiple different epitopes, and reactivity differed depending on the course of the disease and treatment.While certain epitopes most commonly cause T cell reactivity, we did not find evidence for a single or few "dominant" epitopes.
- 1 January 2001
- p. 1387-92
Endocrinology 2000-2100: some thoughts on our future.